Opioid maintenance treatment as a harm reduction tool for opioid-dependent individuals in New York City: The need to expand access to buprenorphine/ naloxone in marginalized populations

Journal of Addictive Diseases

Volumn 31, Issue 3, 2012, Pages 278-287

  Stancliff, Sharon ^a   Joseph, Herman ^b,c   Fong, Chunki ^d   Furst, Terry ^e   Comer, Sandra D ^f   Roux, Perrine ^f,g  

^a Harm Reduction Coalition   (United States)

^b New York State Office of Alcoholism and Substance Abuse Services   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

^d NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES   (United States)

^e JOHN JAY COLLEGE OF CRIMINAL JUSTICE   (United States)

^f NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^g INSERM   (France)

Author keywords

Buprenorphine; drug treatment; harm reduction; heroin; opioid

Indexed keywords

BUPRENORPHINE PLUS NALOXONE;

ADULT; ARTICLE; COMPARATIVE STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HARM REDUCTION; HEALTH PROGRAM; HEROIN DEPENDENCE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; POPULATION; UNITED STATES;

ADULT; BUPRENORPHINE; DRUG COMBINATIONS; ETHNIC GROUPS; FEMALE; HARM REDUCTION; HEALTH SERVICES ACCESSIBILITY; HEROIN DEPENDENCE; HOMELESS PERSONS; HUMANS; MALE; NALOXONE; NARCOTIC ANTAGONISTS; NEEDLE-EXCHANGE PROGRAMS; NEW YORK CITY; OPIATE SUBSTITUTION TREATMENT; PATIENT ACCEPTANCE OF HEALTH CARE; PILOT PROJECTS; SOCIAL MARGINALIZATION; YOUNG ADULT;

EID: 84865229977     PISSN: 10550887     EISSN: 15450848     Source Type: Journal    
DOI: 10.1080/10550887.2012.694603     Document Type: Article

References (36)

1. Sullivan, L E, and, Fiellin, D A. 2008. Narrative review: buprenorphine for opioid-dependent patients in office practice. Ann Intern Med, 148: 662-70. (Pubitemid 351669111)
2. Friedman, S R, Tempalski, B, Cooper, H. 2004. Estimating numbers of injecting drug users in metropolitan areas for structural analyses of community vulnerability and for assessing relative degrees of service provision for injecting drug users. J Urban Health, 81: 377-400. (Pubitemid 39128276)
3. Peterson, J A, Schwartz, R P, Mitchell, S G. 2010. Why don't out-of-treatment individuals enter methadone treatment programmes?. Int J Drug Policy, 21: 36-42.
4. Kraus, M L, Alford, D P, Kotz, M M. 2011. Statement of the American Society of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction. J Addict Med, 5: 254-63.
5. Ducharme, L J, and, Abraham, A J. 2008. State policy influence on the early diffusion of buprenorphine in community treatment programs. Subst Abuse Treat Prev Policy, 3: 17
6. Stein, B D, Gordon, A J, Sorbero, M, Dick, A W, Schuster, J, and, Farmer, C. 2011. The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: Recent service utilization trends in the use of buprenorphine and methadone. Drug Alcohol Depend
7. Sohler, N L, Li, X, Kunins, H V. 2010. Home-versus office-based buprenorphine inductions for opioid-dependent patients. J Subst Abuse Treat, 38: 153-9.
8. Hersh, D, Little, S L, and, Gleghorn, A. 2011. Integrating buprenorphine treatment into a public healthcare system: the San Francisco Department of Public Health's office-based Buprenorphine Pilot Program. J Psychoactive Drugs, 43: 136-45.
9. Alford, D P, LaBelle, C T, Richardson, J M. 2007. Treating homeless opioid dependent patients with buprenorphine in an office-based setting. J Gen Intern Med, 22: 171-6. (Pubitemid 47308806)
10. Carrieri, M P, Amass, L, Lucas, G M, Vlahov, D, Wodak, A, and, Woody, G E. 2006. Buprenorphine use: the international experience. Clin Infect Dis, 43: S197-S215.
11. Emmanuelli, J, and, Desenclos, J C. 2005. Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003. Addiction, 100: 1690-700. (Pubitemid 41626829)
12. Auriacombe, M, Fatseas, M, Dubernet, J, Daulouede, J P, and, Tignol, J. 2004. French field experience with buprenorphine. Am J Addict, 13: S17-S28.
13. Moatti, J P, Carrieri, M P, Spire, B, Gastaut, J A, Cassuto, J P, and, Moreau, J. 2000. Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group. Aids, 14: 151-5. (Pubitemid 30116440)
14. Roux, P, Carrieri, M P, Cohen, J. 2009. Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment. Clin Infect Dis, 49: 1433-40.
15. Comer, S D, Sullivan, M A, Vosburg, S K. 2010. Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. Addiction, 105: 709-18.
16. Rosenheck, R, and, Kosten, T. 2001. Buprenorphine for opiate addiction: potential economic impact. Drug Alcohol Depend, 63: 253-62. (Pubitemid 32545411)
17. King, V L, Burke, C, Stoller, K B. 2008. Implementing methadone medical maintenance in community-based clinics: disseminating evidence-based treatment. J Subst Abuse Treat, 35: 312-21.
18. Bell, J, Burrell, T, Indig, D, and, Gilmour, S. 2006. Cycling in and out of treatment; participation in methadone treatment in NSW, 1990-2002. Drug Alcohol Depend, 81: 55-61. (Pubitemid 41682479)
19. Amodeo, M, Lundgren, L, Chassler, D, and, Witas, J. 2008. High-frequency users of detoxification: who are they?. Subst Use Misuse, 43: 839-49. (Pubitemid 351892447)
20. Roux, P, Tindall, C, Fugon, L. 2012. Impact of inpatient research participation on subsequent heroin use patterns: Implications for ethics and public health. Addiction, 107 (3): 642-9.
21. Bernstein, E, Bernstein, J, Tassiopoulos, K. 2005. Racial and ethnic diversity among a heroin and cocaine using population: treatment system utilization. J Addict Dis, 24: 43-63. (Pubitemid 43334178)
22. Bourgois, P, Martinez, A, Kral, A, Edlin, B R, Schonberg, J, and, Ciccarone, D. 2006. Reinterpreting ethnic patterns among white and African American men who inject heroin: a social science of medicine approach. PLoS Med, 3: e452
23. Perreault, M, Rousseau, M, Mercier, C, Lauzon, P, Gagnon, C, and, Cote, P. 2003. Accessibility to methadone substitution treatment: the role of a low-threshold program. Can J Public Health, 94: 197-200.
24. Spire, B, Lucas, G M, and, Carrieri, M P. 2007. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST). Int J Drug Policy, 18: 262-70. (Pubitemid 47126278)
25. Sullivan, L E, and, Fiellin, D A. 2005. Buprenorphine: its role in preventing HIV transmission and improving the care of HIV-infected patients with opioid dependence. Clin Infect Dis, 41: 891-6. (Pubitemid 41266759)
26. Gossop, M, Marsden, J, Stewart, D, and, Rolfe, A. 1999. Treatment retention and 1 year outcomes for residential programmes in England. Drug Alcohol Depend, 57: 89-98. (Pubitemid 29505142)
27. Roux, P, Villes, V, Blanche, J. 2008. Buprenorphine in primary care: risk factors for treatment injection and implications for clinical management. Drug Alcohol Depend, 97: 105-13.
28. Dasgupta, N, Bailey, E J, Cicero, T. 2010. Post-marketing surveillance of methadone and buprenorphine in the United States. Pain Med, 11: 1078-91.
29. Feroni, I, Peretti-Watel, P, Paraponaris, A. 2005. French general practitioners attitudes and prescription patterns toward buprenorphine maintenance treatment: does doctor shopping reflect buprenorphine misuse?. J Addict Dis, 24: 7-22. (Pubitemid 41542392)
30. Mammen, K, and, Bell, J. 2009. The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence. Expert Opin Pharmacother, 10: 2537-44.
31. Bruce, R D, Govindasamy, S, Sylla, L, Kamarulzaman, A, and, Altice, F L. 2009. Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market. Am J Drug Alcohol Abuse, 35: 68-72.
32. Wesson, D R, and, Smith, D E. 2010. Buprenorphine in the treatment of opiate dependence. J Psychoactive Drugs, 42: 161-75.
33. Cicero, T J, Inciardi, J A, and, Munoz, A. 2005. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004. J Pain, 6: 662-72. (Pubitemid 41395058)
34. Gwin Mitchell, S, Kelly, S M, Brown, B S. 2009. Uses of diverted methadone and buprenorphine by opioid-addicted individuals in Baltimore, Maryland. Am J Addict, 18: 346-55.
35. Bazazi, A R, Yokell, M, Fu, J J, Rich, J D, and, Zaller, N D. 2011. Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users. J Addict Med, 5: 175-80.
36. Ompad, D C, Fuller, C M, Chan, C A, Frye, V, Vlahov, D, and, Galea, S. 2008. Correlates of illicit methadone use in New York City: a cross-sectional study. BMC Public Health, 8: 375